Invention Grant
US07960380B2 Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
失效
异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂
- Patent Title: Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
- Patent Title (中): 异噻唑-3（2H） - 酮1,1-二氧化物的非苯胺衍生物作为肝X受体调节剂
-
Application No.: US12725669Application Date: 2010-03-17
-
Publication No.: US07960380B2Publication Date: 2011-06-14
- Inventor: Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
- Applicant: Anders Broo , Robert Judkins , Lanna Li , Eva-Lotte Lindstedt-Alstermark , Pernilla Sandberg , Marianne Swanson , Lars Weidolf , Kay Brickmann , Patrik Holm
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Agency: Pepper Hamilton LLP
- Priority: SE0500055 20050110
- Main IPC: A61K31/5355
- IPC: A61K31/5355 ; A61K31/501 ; A61K31/4523 ; A61K31/4427 ; A61K31/427 ; A61K31/4255 ; C07D275/02 ; C07D233/54 ; C07D413/02 ; C07D401/02 ; C07D239/02 ; C07D211/00 ; C07D417/02
Abstract:
The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory diseases, Alzheimer's disease, lipid disorders (dyslipidemias) whether or not associated with insulin resistance, type 2 diabetes and other manifestations of the metabolic syndrome, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Public/Granted literature
- US20100227847A1 Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators Public/Granted day:2010-09-09
Information query
